Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liewen Jiang

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|January 23, 2017
On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropoutLingling Li, Shijie Tang, Liewen Jiang
Computational Statistics & Data Analysis|March 22, 2014
Interquantile Shrinkage and Variable Selection in Quantile RegressionLiewen Jiang, Howard D Bondell, Huixia Judy Wang
Journal of Computational and Graphical Statistics : a Joint Publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America|December 24, 2013
Interquantile Shrinkage in Regression ModelsLiewen Jiang, Huixia Judy Wang, Howard D Bondell
Lipids in Health and Disease|April 19, 2015
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndromeCharles Daniel Meyers, Karine Tremblay, Ahmed Amer, et al.
Future Oncology (London, England)|March 12, 2021
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-<i>IDH1</i> cholangiocarcinomaElia Aguado-Fraile, Ania Tassinari, Yuko Ishii, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|January 23, 2017
On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropoutLingling Li, Shijie Tang, Liewen Jiang
Computational Statistics & Data Analysis|March 22, 2014
Interquantile Shrinkage and Variable Selection in Quantile RegressionLiewen Jiang, Howard D Bondell, Huixia Judy Wang
Journal of Computational and Graphical Statistics : a Joint Publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America|December 24, 2013
Interquantile Shrinkage in Regression ModelsLiewen Jiang, Huixia Judy Wang, Howard D Bondell
Lipids in Health and Disease|April 19, 2015
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndromeCharles Daniel Meyers, Karine Tremblay, Ahmed Amer, et al.
Future Oncology (London, England)|March 12, 2021
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-<i>IDH1</i> cholangiocarcinomaElia Aguado-Fraile, Ania Tassinari, Yuko Ishii, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Pageof 1